Literature DB >> 16003232

Markers of inflammation before and after renal transplantation.

Alfonso M Cueto-Manzano1, Luis E Morales-Buenrostro, Liliana González-Espinoza, Norma González-Tableros, Fabiola Martín-del-Campo, Ricardo Correa-Rotter, Isela Valera, Josefina Alberú.   

Abstract

BACKGROUND: This study aims to compare serum C-reactive protein (CRP), interleukin (IL-6), and tumor necrosis factor (TNF)-alpha in end-stage renal disease (ESRD) patients before versus after receiving renal transplantation (RT) and versus donors.
METHODS: Serum samples from 37 ESRD patients (24 male, age 34+/-13 years) were collected before and after RT; in addition, samples from 31 donors were obtained at transplantation. CRP concentrations were measured using nephelometry, and TNF-alpha and IL-6 were measured by enzyme-linked immunoadsorbent assay.
RESULTS: Ninety-two percent of recipients had a living donor, 73% received cyclosporine A, 27% tacrolimus, and 70% induction with daclizumab. Thirteen percent had acute rejection and 16% chronic allograft nephropathy. All inflammation markers decreased 6 months after RT, but only CRP was below baseline values (baseline: 5.0+/-3.5; 6 months: 3.0+/-0; 12 months: 3.2+/-0.7; 18 months: 3.2+/-0.6; donors: 3.6+/-1.5 mg/L; P<0.05), whereas median TNF-alpha (baseline: 0.1 [0.03-0.2]; 6 months: 0 [0-0.1]; 12 months: 0.3 [0.1-2.6]; 18 months: 0.6 [0.1-1.9]; donors: 0 [0-0.1] pg/mL; P<0.05) and IL-6 (baseline: 1.9 [1.2-7.1]; 6 months: 1.2 [0.6-28.3]; 12 months: 2.6 [1.3-3.4]; 18 months: 2.7 [1.7-4.2]; donors: 1.1 [0.6-1.9] pg/mL; P<0.05) significantly increased up to the end of follow-up. Before RT, CRP correlated with age (r 0.45, P=0.006) and albumin (r -0.36, P=0.04). TNF-alpha and IL-6 were correlated before (r 0.34, P=0.04) and after (r 0.55, P=0.02) RT. Inflammation markers were not different in patients who had acute rejection episodes or chronic nephropathy.
CONCLUSIONS: Compared with controls, patients displayed an inflammatory phenomenon before receiving RT. Serum CRP decreased significantly after RT, whereas TNFalpha and IL-6 increased.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003232     DOI: 10.1097/01.tp.0000164348.16689.03

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  20 in total

1.  Effects of exercise in renal transplant recipients.

Authors:  Giulio Romano; Eric Lorenzon; Domenico Montanaro
Journal:  World J Transplant       Date:  2012-08-24

Review 2.  Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.

Authors:  Cameron McDonald-Hyman; Laurence A Turka; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2015-03-25       Impact factor: 17.956

3.  Predictors and prognostic implications of major adverse cardiovascular events after renal transplant: 10 years outcomes in 321 patients.

Authors:  Waqas Aftab; Padmini Varadarajan; Shuja Rasool; Ramdas G Pai
Journal:  Int J Angiol       Date:  2014-06

4.  Inflammation and oxidation: do they improve after kidney transplantation? Relationship with mortality after transplantation.

Authors:  Laura Cañas; Eva Iglesias; María Cruz Pastor; Jaume Barallat; Javier Juega; Ioana Bancu; Ricardo Lauzurica
Journal:  Int Urol Nephrol       Date:  2016-12-24       Impact factor: 2.370

5.  Renal Transplantation in Romania: Where Do We Stand?

Authors:  Gabriel Stefan; Liliana Garneata; Dorina Tacu; Cristina Bucsa; Ioanel Sinescu; Gabriel Mircescu
Journal:  Maedica (Bucur)       Date:  2015-09

6.  Anemia and low-grade inflammation in pediatric kidney transplant recipients.

Authors:  Jenni Miettinen; Juuso Tainio; Timo Jahnukainen; Mikko Pakarinen; Jouni Lauronen; Hannu Jalanko
Journal:  Pediatr Nephrol       Date:  2016-08-30       Impact factor: 3.714

7.  Correlates of the severity of coronary atherosclerosis in long-term kidney transplant patients.

Authors:  Hyun-Wook Kim; Shin-Wook Kang; Ho Yung Lee; Dong-Hoon Choi; Won-Heum Shim; Soon Il Kim; Yu Seun Kim; Kyu Hun Choi
Journal:  J Korean Med Sci       Date:  2010-04-22       Impact factor: 2.153

8.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Infection       Date:  2018-09-25       Impact factor: 3.553

9.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  J Nephrol       Date:  2018-09-25       Impact factor: 3.902

10.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Intern Emerg Med       Date:  2018-09-25       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.